Table 1 Preclinical and clinical trials using chimeric rAd.

Ovarian cancer

Enadenotucirev (ColoAd1)

Ad11p/Ad3

Intravenous

Phase I

NCT02028117

[50]

Paclitaxel

Colorectal cancer

Head and neck cancer

Epithelial tumor

Intravenous

Phase I

NCT02636036

[51]

Nivolumab

Rectal cancer

Intravenous

Phase I

NCT03916510

[52]

Capecitabine, radiotherapy

Lung cancer

NG-347

Ad11p/Ad3

IFNα, MIP1α and CD80

Preclinical

[53]

CAR-T

Epithelial tumor

NG-348

Ad11p/Ad3

Anti-CD3 and anti-CD80

Intravenous

Phase II

NCT02028442

[49]

Colon carcinoma

Lung cancer

Bladder cancer

NG-641

Ad11p/Ad3

CD40L, FAP/CD3, CXCL9/10, IFNα

Intravenous,

Intratumoral

Phase I

NCT02053220

[54]

Tumor resection

Metastatic cancer

Epithelial tumor

NG-350A

CD40L

Intravenous,

Intratumoral

Phase I

NCT03852511

[55]

Ovarian cancer

ONCOS-102

Ad5/3-∆24-GM-CSF

GM-CSF

Intracavitary

Preclinical

[9]

Peritoneal malignancy

Intraperitoneal

Phase II

NCT02963831

Durvalumab, cyclophosphamide

Solid tumor

Intratumoral

Phase I

NCT01598129

[63]

Mesothelioma

Intratumoral

Phase II

NCT02879669

[64]

Pemetrexed, ​cisplatin

Multiple myeloma

LOAd700

Ad5/35-E2F-∆24-CD40L

CD40L

Preclinical

[58]

Solid tumor

LOAd703

Ad5/35-E2F-∆24-CD40L-4-1BBL

CD40L, 4-1BBL

Intratumoral

Phase II

Phase II

Phase II

NCT03225989

NCT04123470

NCT03555149

Atezolizumab, regorafenib, imprime PGG

Pancreatic cancer

Phase II

NCT02705196

Gemcitabine, nab-paclitaxel

Pancreatic cancer

Peritumoral

Preclinical

[61, 62]

Gemcitabine

Lymphoma

Intratumoral

Preclinical

[59]

CAR-T

Melanoma

Exosome-LOAd703

Ad5/35-E2F-∆24-CD40L-4-1BBL

Exosome delivery

Intratumoral

Preclinical

[60]

Melanoma

LOAd732

Ad5/35-E2F-∆24-CD40L-4-1BBL-IL-2

CD40L, 4-1BBL, IL-2

Intratumoral

Preclinical

[6]